Method for preparing TDP-43 CTDA315E protein antigen and method for preparing specific IgY egg yolk antibody of TDP-43 CTDA315E protein antigen

The TDP-43 CTDA315E protein antigen was prepared by gene recombination and the use of yolk antibody technology solved the problem that it was difficult to obtain specific antibodies in traditional antibody preparation methods, and achieved efficient and specific antibody preparation, which was used to diagnose TDP-43-related diseases and Research provides important tools.

CN119040365APending Publication Date: 2024-11-29SHAANXI SCI TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411012214.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-29

Smart Images

  • Figure CN119040365A_ABST
    Figure CN119040365A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a TDP-43 CTDA315E protein and an egg yolk antibody (IgY) thereof, and belongs to the technical field of antibodies. The method comprises the following steps: preparing a TDP-43 CTDA315E mutant protein antigen by adopting a gene recombination technology, efficiently expressing and purifying the protein through BL21 (DE3) escherichia coli, emulsifying the purified protein antigen, injecting the emulsified protein antigen into a healthy laying hen body for immunization, and extracting an IgY antibody from the immunized egg. The anti-TDP-43 CTDA315E egg yolk antibody disclosed by the invention can be effectively combined with TDP-43 CTDA315E protein, the titer can be up to 1: 3000, and the antibody has the advantages of high sensitivity, strong specificity and reliable detection result when being used for detecting the content of TDP-43 CTDA315E in an ALS model mouse brain slice, is beneficial to diagnosis, dynamic monitoring and prognosis evaluation of neurodegenerative diseases and the like, and has relatively high clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the preparation and application of specific IgY antibodies in the field of antibody technology, and in particular to a TDP-43 CTD A315E Method for preparing mutant protein antigen and targeting TDP-43 CTD A315E Preparation method of IgY yolk antibody of protein and its application. Background Art

[0002] In the field of protein biochemistry and biomedical research, TDP-43 (TAR DNA-binding protein 43, TDP-43) is a highly conserved nuclear DNA / RNA binding protein. Its molecular structure includes a partially folded N-terminal domain (NTD), two tandem domains that recognize RNA (RRM1&RRM2), and a C-terminal prion-like domain (CTD). Previous studies have shown that TDP-43 CTD (263-414aa) is the main region involved in the liquid-liquid phase separation of the full-length protein. This physical process plays an important role in its regulation of biological processes such as RNA metabolism, mitochondrial function, stress response and protein aggregation. CTD contains almost all mutations associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTLD), and is the main role in TDP-43 aggregation and pathology. Among them, CTD A315E The mutation stabilizes the R-shaped folding by forming salt bridges and hydrophobic interactions, promoting the irreversible liquid-solid phase transition of the aggregates formed by TDP-43 phase separation and aggregation in the cytoplasm, leading to neurotoxicity.

[0003] Given that TDP-43 CTD A315E Due to the important role of mutations in neurodegenerative diseases, it is increasingly being studied as a major antigenic target for the disease. However, due to the complex structure and high conservation of TDP-43 CTD, there are certain challenges in preparing antibodies against this specific region. Traditional antibody preparation methods (such as mouse or rabbit antibody preparation) make it difficult to obtain specific antibodies against TDP-43CTD. Yolk antibodies (IgY) have gradually become an important tool in biomedical research due to their relatively simple preparation process, high yield, no mammalian pathogen contamination and low cross-reactivity. Therefore, targeting TDP-43 CTD A315E The development of an efficient method for preparing egg yolk antibodies is of great significance for the basic research and diagnosis of TDP-43 related diseases.

[0004] This patent provides a method for preparing TDP-43 CTD A315EThe method of preparing protein and its specific IgY yolk antibody and verifying the potential of the antibody in related applications. This method can not only improve the efficiency of antibody preparation, but also significantly improve the specificity and affinity of the antibody, providing a powerful tool for TDP-43 related research. Summary of the invention

[0005] The first object of the present invention is to provide a TDP-43 CTD A315E A method for preparing a mutant protein antigen; Another object of the present invention is to provide a TDP-43 CTD A315E Method for preparing egg yolk antibody.

[0006] The first object of the present invention is to provide a TDP-43 CTD A315E A method for preparing a mutant protein antigen, the method comprising the following steps: (1) The full-length TDP-43 gene was used as a template to design TDP-43 CTD gene cloning primers, and the TDP-43 CTD gene was amplified by PCR. It was then cloned into the modified vector pET28a with 6 His residues at the C-terminus using Nco I and Xho I restriction endonucleases and T4 ligase; (2) A commercial site-directed mutagenesis kit was used to introduce the A315E mutation into the TDP-43 CTD region to obtain TDP-43 A315E pET28a recombinant plasmid; It should be noted that the antigenic epitope of TDP-43 CTD protein (263-414aa) is: KHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM Specific primers include: Primer F-Nco I: 5'-CATG CCATGGGC AAGCACAACAGCAACCGCC-3' Primer R-Xho I: 5′-CCG CTCGAG CATACCCCAGCCAGAGCTTTTG-3′ The optimized nucleic acid sequence of TDP-43 CTD protein is as follows: Aagcacaacagcaaccgccagctggaacgttccggtcgcttcggcggcaacccgggtggttttggcaaccaaggtggctttggcaatagccgtggtggcggagccggtctgggt aacaaccaaggttctaacatgggtggtggcatgaattttggtgcgttcagcattaacccggcaatgatggctgctgcgcaagcagctctgcagtcatcctggggtatgatgggt atgctggcatcacaacagaatcaaagcggtccgtctggcaacaaccaaaaccaaggcaatatgcagcgtgagccgaatcaagcgtttgggtctggcaacaatagctattccggc tcgaactcgggcgctgcgattggttggggtagcgcgtctaacgcgggcagcggcagcggcttcaacggtggtttcggttcctctatggactccaaaagctctggctggggtatg (3) The above recombinant plasmid was transformed into Escherichia coli BL21 (DE3) to obtain recombinant genetically engineered bacteria, and then induced expression and nickel column purification were performed.

[0007] The conditions for culture and induction expression are: 37°C, 220rpm for about 2.5-3 hours. When the OD value reaches 0.6-0.9, 0.5mM IPTG is added for induction. Then, culture is continued at 37°C, 180-200 rpm for about 5-7 hours, and the bacteria are collected.

[0008] Recombinant TDP-43 CTD A315EThe protein purification steps are as follows: the protein bacteria were fully resuspended in 30 mL of lysis buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 1 mM PMSF), and the bacteria were disrupted by ultrasound in an ice-water mixture (300 W, 5 s-5 s-10 min). After disruption, the supernatant and precipitate were obtained by centrifugation, and the supernatant was filtered through a 0.45 μM PVDF filter and then purified by a nickel column. The column was loaded with 2 mL of filler, and the nickel column was equilibrated with binding buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT) before loading. The column was then washed with 4-5 column volumes of binding buffer, and the impurities were washed 6 times with 8-10 column volumes of washing buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 50 mM imidazole, 1 mM DTT). The target protein was eluted twice with 2 column volumes of elution buffer (pH 8.0, 8 M urea, 20 mMTris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 500 mM imidazole), and TDP-43 CTD was obtained after treatment with a desalting column and ultrafiltration and concentration. A315E Protein antigen.

[0009] The second object of the present invention is to provide an anti-TDP-43 CTD A315E A method for preparing avian polyclonal antibodies, the method comprising the following steps: (1) Gene recombination was used to prepare the TDP-43 CTD pET28a expression vector, and then a commercial site-directed mutagenesis kit was used to prepare TDP-43 CTD A315E Protein antigen, i.e., the antigen is prepared by the above method; (2) The antigen obtained in step (1) is mixed with Freund's complete adjuvant at a ratio of 1:1 and then emulsified as the primary immunization antigen; Freund's incomplete adjuvant is selected and mixed with the above antigen at a ratio of 1:1 and then emulsified as the booster immunization antigen; (3) Preparation of anti-TDP-43 CTD A315E Antigen-specific antibodies, wherein the immune antigen obtained in the first object of the invention is injected into laying hens, and the eggs produced by the poultry are collected, marked and stored at 4°C; (4) Extracting IgY, wherein the yolk and egg white are separated from the eggs collected as described above, and then IgY polyclonal antibodies are extracted.

[0010] It should be noted that the method for preparing immunoglobulin includes: using TDP-43 CTD A315EThe antigen was initially injected into the breast muscle of 16-week-old laying hens at multiple points for the first immunization, with the immunization dose being 200-300 μg / hen. Fourteen days after the initial immunization, three booster immunizations were performed with an interval of 14 days and the immunization dose being 100-250 μg / hen.

[0011] It should be noted that the method for extracting IgY using the PEG6000 precipitation method includes the following steps: (1) Separate the yolk from the collected immune chicken eggs and dilute it with physiological saline 3 times the volume of the yolk; (2) Place the mixture in a centrifuge tube and centrifuge at 4 °C, 10,000-12,000 rpm for 10-20 minutes to collect the supernatant; (3) Add PEG6000 to the supernatant to a final concentration of 3.5% (w / v) and gently stir to completely dissolve PEG6000. (4) After standing at room temperature for 30-60 minutes, centrifuge at 10,000-12,000 rpm for 10-20 minutes at 4 °C and collect the supernatant; (5) Add PEG6000 to the supernatant to a final concentration of 12% (w / v) and gently stir to completely dissolve PEG6000. (6) After standing at room temperature for 30-60 minutes, centrifuge at 10,000-12,000 rpm for 10-20 minutes at 4 °C to collect the precipitate; (7) Resuspend the precipitate in PBS with a volume of 1 / 10 of the original egg yolk volume and mix well using a vortex mixer to ensure that the precipitate is completely dissolved.

[0012] (8) Divide the extracted IgY antibody solution into centrifuge tubes, mark them and store them at -80 °C.

[0013] It should be noted that all the above steps were carried out at 4 °C to reduce protein degradation.

[0014] It should be noted that the method for extracting IgY antibodies based on the protein liquid-liquid phase separation principle includes the following steps: (1) Separate the yolk from the collected immune chicken eggs, and mix the 60% PEG8000 (w / v) mother solution with the yolk solution to make the final concentration of PEG8000 be 10%; (2) 4 °C, 40-60 rpm, mix for 20-60 min, then let stand for 30 min; (3) Centrifuge the mixture at 4°C, 10,000-12,000 rpm for 30-60 minutes and collect the supernatant; (4) Filter the supernatant through filter paper and collect the filtrate into a new test tube; (5) Mix the PEG8000 mother solution and the filtrate to a final PEG8000 concentration of 15% at 4 °C, 30-60 rpm, and mix for 10-30 minutes; (6) Centrifuge the mixture at 4°C, 10,000-12,000 rpm for 30-60 minutes to precipitate the separated IgY and discard the supernatant. (7) Dissolve the precipitate with 5-10 mL PBS buffer (0.01 M, pH 7.0-7.4), and dialyze overnight at 4 °C using PBS buffer to obtain IgY antibody. Divide the IgY antibody solution into centrifuge tubes, label them, and store them at -80 °C.

[0015] The beneficial effects of the present invention are: The present invention provides a method for preparing TDP-43 CTD A315E The protein and its anti-yolk antibody method are used to explore its application in medical research. The protein mimics TDP-43CTD in ALS (amyotrophic lateral sclerosis) through targeted mutagenesis A315E Gene mutations help study the pathophysiological process of ALS, provide key tools for discovering and developing treatments for ALS, and accelerate the discovery and screening of new drugs. In addition, the prepared anti-yolk antibodies can be used to detect TDP-43 CTD A315E The presence of TDP-43 CTD can help early diagnosis and prevention of ALS and related neurodegenerative diseases, and provide patients with earlier treatment intervention and preventive measures. A315E The properties and functions of the protein can deepen the understanding of the mechanism of action of TDP-43 protein in nervous system diseases and provide a theoretical basis for future disease treatment and prevention. In addition, compared with the prior art, the anti-TDP-43 CTD developed by the present invention A315E The antibody has high specificity and sensitivity, good detection effect, and the method and steps for preparing the antibody are simple and convenient. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 To purify TDP-43 CTD A315E Polyacrylamide electrophoresis results of proteins, including: M: marker; lane 1: TDP-43CTD A315E protein; Figure 2 Detection of specific IgY and TDP-43 CTD by WB A315E combination. DETAILED DESCRIPTION

[0017] The above contents of the present invention are further described in detail below through embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0018] Example 1: A TDP-43 CTD A315E The method for preparing a mutant protein antigen comprises the following steps: (1) The full-length TDP-43 gene was used as a template to design TDP-43 CTD gene cloning primers, and the TDP-43 CTD gene was amplified by PCR. It was then cloned into the modified vector pET28a with 6 His residues at the C-terminus using Nco I and Xho I restriction endonucleases and T4 ligase; (2) A commercial site-directed mutagenesis kit was used to introduce the A315E mutation into the TDP-43 CTD region; It should be noted that the antigenic epitope of TDP-43 CTD protein (263-414aa) is: KHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM Specific primers include: Primer F-Nco I: 5'-CATG CCATGGGC AAGCACAACAGCAACCGCC-3' Primer R-Xho I: 5′-CCG CTCGAG CATACCCCAGCCAGAGCTTTTG-3′ The optimized nucleic acid sequence of TDP-43 CTD protein is as follows: aagcacaacagcaaccgccagctggaacgttccggtcgcttcggcggcaacccgggtggttttggcaaccaaggtggctttggcaatagccgtggtggcggagccggtctgggt aacaaccaaggttctaacatgggtggtggcatgaattttggtgcgttcagcattaacccggcaatgatggctgctgcgcaagcagctctgcagtcatcctggggtatgatgggt atgctggcatcacaacagaatcaaagcggtccgtctggcaacaaccaaaaccaaggcaatatgcagcgtgagccgaatcaagcgtttgggtctggcaacaatagctattccggc tcgaactcgggcgctgcgattggttggggtagcgcgtctaacgcgggcagcggcagcggcttcaacggtggtttcggttcctctatggactccaaaagctctggctggggtatg (3) The above recombinant plasmid was transformed into Escherichia coli BL21 (DE3) to obtain recombinant genetically engineered bacteria, and then induced expression and nickel column purification were performed.

[0019] The conditions for culture and induction expression are: 37°C, 220 rpm for about 2.5-3 hours. When the OD value reaches 0.6-0.9, 0.5 mM IPTG is added for induction. Then, culture is continued at 37°C, 180-200 rpm for about 5-7 hours, and the bacteria are collected.

[0020] Recombinant TDP-43 CTD A315EThe protein purification steps are as follows: the protein bacteria were fully resuspended in 30 mL of lysis buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 1 mM PMSF), and the bacteria were disrupted by ultrasound in an ice-water mixture (300 W, 5 s-5 s-10 min). After disruption, the supernatant and precipitate were obtained by centrifugation, and the supernatant was filtered through a 0.45 μM PVDF filter and then purified by a nickel column. The column was loaded with 2 mL of filler, and the nickel column was equilibrated with binding buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT) before loading. The column was then washed with 4-5 column volumes of binding buffer, and the impurities were washed 6 times with 8-10 column volumes of washing buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 50 mM imidazole, 1 mM DTT). The target protein was eluted twice with 2 column volumes of elution buffer (pH 8.0, 8 M urea, 20 mMTris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 500 mM imidazole), and TDP-43 CTD was obtained after treatment with a desalting column and ultrafiltration and concentration. A315E Protein antigen.

[0021] Example 2: Anti-TDP-43 CTD A315E The method for preparing avian polyclonal antibodies comprises the following steps: (1) Gene recombination was used to prepare the TDP-43 CTD pET28a expression vector, and then a commercial site-directed mutagenesis kit was used to prepare TDP-43 CTD A315E Protein antigen, i.e., the antigen is prepared by the method of Example 1; (2) The antigen obtained in step (1) is mixed with Freund's complete adjuvant at a ratio of 1:1 and then emulsified as the primary immunization antigen; Freund's incomplete adjuvant is selected and mixed with the above antigen at a ratio of 1:1 and then emulsified as the booster immunization antigen; (3) Preparation of anti-TDP-43 CTD A315E Antigen-specific antibodies, wherein the immune antigen prepared in Example 1 is injected into laying hens, and the eggs produced by the poultry are collected, marked, and stored at 4°C; (4) Extracting IgY, wherein the yolk and egg white are separated from the eggs collected as described above, and then IgY polyclonal antibodies are extracted.

[0022] It should be noted that the method for preparing immunoglobulin includes: using TDP-43 CTD A315EThe antigen was initially injected into the breast muscle of 16-week-old laying hens at multiple points for the first immunization, with the immunization dose being 200-300 μg / hen. Fourteen days after the initial immunization, three booster immunizations were performed with an interval of 14 days and the immunization dose being 100-250 μg / hen.

[0023] It should be noted that the method for extracting IgY using the PEG6000 precipitation method includes the following steps: (1) Separate the yolk from the collected immune chicken eggs and dilute it with physiological saline 3 times the volume of the yolk; (2) Place the mixture in a centrifuge tube and centrifuge at 4 °C, 10,000-12,000 rpm for 10-20 minutes to collect the supernatant; (3) Add PEG6000 to the supernatant to a final concentration of 3.5% (w / v) and gently stir to completely dissolve PEG6000. (4) After standing at room temperature for 30-60 minutes, centrifuge at 10,000-12,000 rpm for 10-20 minutes at 4 °C and collect the supernatant; (5) Add PEG6000 to the supernatant to a final concentration of 12% (w / v) and gently stir to completely dissolve PEG6000. (6) After standing at room temperature for 30-60 minutes, centrifuge at 10,000-12,000 rpm for 10-20 minutes at 4 °C to collect the precipitate; (7) Resuspend the precipitate in PBS with a volume of 1 / 10 of the original egg yolk volume and mix well using a vortex mixer to ensure that the precipitate is completely dissolved.

[0024] (8) Divide the extracted IgY antibody solution into centrifuge tubes, mark them and store them at -80 °C.

[0025] It should be noted that all the above steps were carried out at 4 °C to reduce protein degradation.

[0026] It should be noted that the method for extracting IgY antibodies based on the protein liquid-liquid phase separation principle includes the following steps: (1) Separate the yolk from the collected immune chicken eggs, and mix the 60% PEG8000 (w / v) mother solution with the yolk solution to make the final concentration of PEG8000 be 10%; (2) 4 °C, 40-60 rpm, mix for 20-60 min, then let stand for 30 min; (3) Centrifuge the mixture at 4°C, 10,000-12,000 rpm for 30-60 minutes and collect the supernatant; (4) Filter the supernatant through filter paper and collect the filtrate into a new test tube; (5) Mix the PEG8000 mother solution and the filtrate to a final PEG8000 concentration of 15% at 4 °C, 30-60 rpm, and mix for 10-30 minutes; (6) Centrifuge the mixture at 4°C, 10,000-12,000 rpm for 30-60 minutes to precipitate the separated IgY and discard the supernatant. (7) Dissolve the precipitate with 5-10 mL PBS buffer (0.01 M, pH 7.0-7.4), and dialyze overnight at 4 °C using PBS buffer to obtain IgY antibody. Divide the IgY antibody solution into centrifuge tubes, label them, and store them at -80 °C.

[0027] This patent is not limited to PBS. Buffer solutions of carbonate, Tris-HCl or other salts with a pH value in the range of 7-8 are all within the protection scope of this patent.

[0028] Example 3: Immunohistochemical Validation of TDP-43 CTD in ALS Mouse Model A315E Polyclonal antibody specificity (1) Preparation of brain slices: fix freshly dissected tissue (<3 mm thick) with 2% paraformaldehyde overnight at room temperature; rinse the tissue with running water for 5 minutes, dehydrate the tissue with 70%, 80%, and 95% alcohol for 5 minutes each, dehydrate with 100% alcohol for 3 times for 5 minutes each, and clear the tissue in xylene for 2 times for 5 minutes each; embed the tissue in paraffin blocks, cut the paraffin-embedded tissue blocks into 5-8 μm thickness on a microtome, float in a 40 °C distilled water bath, and transfer the slices to slides at room temperature to dry overnight; (2) Dewaxing and rehydration: Dewax the slides in xylene twice for 5 minutes each time. Place the slides in 100% alcohol twice for 3 minutes each time, then place them in 95%, 70% and 50% alcohol once for 3 minutes each time, and wash with PBS three times for 5 minutes each time. (3) Endogenous peroxidase blocking: Incubate the sections in 3% H2O2 in methanol solution at room temperature for 10 min to block endogenous peroxidase activity, and then rinse with PBS twice, 5 min each time; (4) High-temperature heat repair of antigens: Place the slide in a staining container, pour 300 mL of 10 mM citrate buffer (pH 6.0) into the staining container, incubate at 95-100 °C for 10 minutes, then move the staining container to room temperature, cool the slide for 20 minutes, and rinse the slide twice with PBS for 5 minutes each time; (5) Add 100 μL of 10% fetal bovine serum PBS solution to the tissue section on the slide, incubate at room temperature in a humidified chamber for 1 hour, and then air-dry the blocking solution on the slide; (6) Cover the tissue sections on the slides with the primary antibody (1:3000), incubate at room temperature in a humidified chamber for 1 hour, and rinse the slides twice with PBS for 5 minutes each; It should be noted that the method for preparing the primary antibody includes: diluting the anti-TDP-43 CTD with a 0.5% bovine serum albumin PBS solution A315E Antibody.

[0029] (7) Cover the sections on the slides with secondary antibody (1:8000) and incubate at room temperature in a humidified chamber for 30 min. Rinse the slides twice with PBS for 5 min each. It should be noted that: in addition to HRP-labeled rabbit anti-chicken enzyme-labeled secondary antibodies, other HRP-labeled mouse anti-chicken, horse anti-chicken, goat anti-chicken enzyme-labeled secondary antibodies can be applied to the established immunohistochemistry method, but are not limited to these HRP enzyme-labeled secondary antibodies. The biotin-labeled antibody and streptavidin-labeled horseradish peroxide (biotin / SA-HRP) system are all within the scope of protection of this patent.

[0030] (8) Color development: Cover the sections on the slide with 100 μL of DAB substrate solution (freshly prepared before use: 0.05% DAB-0.015% H2O2 in PBS solution) and develop for <5 min until the desired color intensity is reached. Rinse the slides 3 times with PBS for 2 min each. (9) Counterstaining: Immerse the slide in hematoxylin for 1-2 minutes to counterstain the slide, and then rinse the slide with running water for 10 minutes; (10) Dehydration and transparency: Dehydrate the tissue slides with alcohol (95%, 95%, 100% and 100%) for 5 minutes each time, wash the tissue slides with xylene for 3 times, and seal the coverslips with sealing agent. The sealed slides can be stored permanently at room temperature; (11) Observation and analysis: It was clearly observed under a microscope that IgY polyclonal antibody could specifically recognize and bind to the CTD of TDP-43 protein in the mouse model. A315E Mutation areas are characterized by obvious positive staining signals in cells or tissues where the mutant protein is present. In addition, in ALS mouse models, TDP-43 protein may be translocated from the nucleus to the cytoplasm and form inclusion bodies, as these areas show strong staining signals.

Claims

1. A method for preparing TDP-43 CTD A315E The method for producing a protein antigen is characterized in that The steps include: (1) The full-length TDP-43 gene was used as a template to design TDP-43 CTD gene cloning primers, and the TDP-43 CTD gene was amplified by PCR. It was then cloned into the modified vector pET28a with 6 His residues at the C-terminus using Nco I and Xho I restriction endonucleases and T4 ligase; (2) A commercial site-directed mutagenesis kit was used to introduce the A315E mutation into the TDP-43 CTD region to obtain TDP-43 A315E pET28a recombinant plasmid; The antigenic epitope of the TDP-43 CTD protein (263-414aa) is: KHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM The TDP-43 CTD gene cloning primers include: Primer F-Nco I: 5'-CATG CCATGGGC AAGCACAACAGCAACCGCC-3' Primer R-Xho I: 5′-CCG CTCGAG CATACCCCAGCCAGAGCTTTTG-3′ (3) The above recombinant plasmid was transformed into Escherichia coli BL21 (DE3) to obtain recombinant genetically engineered bacteria, which were induced for expression and purified by nickel column to obtain TDP-43 CTD A315E Protein antigen.

2. The method for preparing TDP-43 CTD according to claim 1 A315E The method for producing a protein antigen is characterized in that The optimized nucleic acid sequence of TDP-43 CTD protein is as follows: Aagcacaacagcaaccgccagctggaacgttccggtcgcttcggcggcaacccgggtggttttggcaaccaaggtggctttggcaatagccgtggtggcggagccggtctgggt aacaaccaaggttctaacatgggtggtggcatgaattttggtgcgttcagcattaacccggcaatgatggctgctgcgcaagcagctctgcagtcatcctggggtatgatgggt atgctggcatcacaacagaatcaaagcggtccgtctggcaacaaccaaaaccaaggcaatatgcagcgtgagccgaatcaagcgtttgggtctggcaacaatagctattccggc tcgaactcgggcgctgcgattggttggggtagcgcgtctaacgcgggcagcggcagcggcttcaacggtggtttcggttcctctatggactccaaaagctctggctggggtatg.

3. The method for preparing TDP-43 CTD according to claim 1 A315E The method for producing a protein antigen is characterized in that The steps of step (3) are as follows: The conditions for culture and induction expression are: 37°C, 220 rpm for about 2.5-3 hours. When the OD value reaches 0.6-0.9, 0.5 mM IPTG is added for induction. Then, culture is continued at 37°C, 180-200 rpm for about 5-7 hours, and the bacteria are collected. Recombinant TDP-43 CTD A315E The protein purification steps are as follows: the protein bacteria were fully resuspended in 30 mL of lysis buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 1mM PMSF), and the bacteria were disrupted by ultrasound in an ice-water mixture (300 W, 5 s-5 s-10 min); after disruption, the supernatant and precipitate were obtained by centrifugation, and the supernatant was filtered using a 0.45 μM PVDF filter membrane and then purified by a nickel column; 2 mL of filler was used to load the column, and the nickel column was equilibrated with binding buffer (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT) and then loaded, and then 4-5 times the column volume of binding buffer was used for washing, and 8-10 times the column volume of washing solution (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 50 mM imidazole, 1 mM The impurities were washed with 2 column volumes of eluent (pH 8.0, 8 M urea, 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 500 mM imidazole) to elute the target protein. The TDP-43 CTD was obtained after treatment with a desalting column and ultrafiltration concentration. A315E Protein antigen.

4. A TDP-43 CTD A315E A method for preparing egg yolk antibodies, characterized in that: (1) Gene recombination was used to prepare the TDP-43 CTD pET28a expression vector, and then a commercial site-directed mutagenesis kit was used to prepare TDP-43 CTD A315E Protein antigen, that is, the antigen is prepared by any method of claims 1 to 3; (2) The antigen obtained in step (1) is mixed with Freund's complete adjuvant at a ratio of 1:1 and then emulsified as the primary immunization antigen; Freund's incomplete adjuvant is selected and mixed with the above antigen at a ratio of 1:1 and then emulsified as the booster immunization antigen; (3) Preparation of anti-TDP-43 CTD A315E Antigen-specific antibodies, wherein the immune antigen obtained in the first object of the invention is injected into laying hens, and the eggs produced by the poultry are collected, marked and stored at 4°C; (4) Extracting IgY, wherein the yolk and egg white are separated from the eggs collected as described above, and then IgY polyclonal antibodies are extracted.

5. The method for preparing TDP-43 CTDA315E yolk antibody according to claim 4, characterized in that: The method for preparing immunoglobulin comprises: using TDP-43 CTD A315E The antigen was initially injected into the breast muscle of 16-week-old laying hens at multiple points for the first immunization, with the immunization dose being 200-300 μg / hen. Fourteen days after the initial immunization, three booster immunizations were performed with an interval of 14 days and the immunization dose being 100-250 μg / hen.

6. The method for preparing TDP-43 CTDA315E yolk antibody according to claim 4, characterized in that: The method for extracting IgY using the PEG6000 precipitation method comprises the following steps: (1) Separate the yolk from the collected immune chicken eggs and dilute it with physiological saline 3 times the volume of the yolk; (2) Place the mixture in a centrifuge tube and centrifuge at 4 °C, 10,000-12,000 rpm for 10-20 minutes to collect the supernatant; (3) Add PEG6000 to the supernatant to a final concentration of 3.5% (w / v) and gently stir to completely dissolve PEG6000. (4) After standing at room temperature for 30-60 minutes, centrifuge at 10,000-12,000 rpm for 10-20 minutes at 4 °C and collect the supernatant; (5) Add PEG6000 to the supernatant to a final concentration of 12% (w / v) and gently stir to completely dissolve PEG6000. (6) After standing at room temperature for 30-60 minutes, centrifuge at 10,000-12,000 rpm for 10-20 minutes at 4 °C to collect the precipitate; (7) Resuspend the precipitate in PBS with a volume of 1 / 10 of the original egg yolk volume and mix evenly using a vortex mixer to ensure that the precipitate is completely dissolved; (8) Divide the extracted IgY antibody solution into centrifuge tubes, mark them and store them at -80 °C.

7. The method for preparing TDP-43 CTDA315E yolk antibody according to claim 4, characterized in that: All the above steps were carried out at 4 °C to reduce protein degradation.

8. The method for preparing TDP-43 CTDA315E yolk antibody according to claim 4, characterized in that: The method for extracting IgY antibodies based on the protein liquid-liquid phase separation principle comprises the following steps: (1) Separate the yolk from the collected immune chicken eggs, and mix the 60% PEG8000 (w / v) mother solution with the yolk solution to make the final concentration of PEG8000 be 10%; (2) 4 °C, 40-60 rpm, mix for 20-60 min, then let stand for 30 min; (3) Centrifuge the mixture at 4°C, 10,000-12,000 rpm for 30-60 minutes and collect the supernatant; (4) Filter the supernatant through filter paper and collect the filtrate into a new test tube; (5) Mix the PEG8000 mother solution and the filtrate to a final PEG8000 concentration of 15% at 4 °C, 30-60 rpm, and mix for 10-30 minutes; (6) Centrifuge the mixture at 4°C, 10,000-12,000 rpm for 30-60 minutes to precipitate the separated IgY and discard the supernatant. (7) Dissolve the precipitate with 5-10 mL PBS buffer (0.01 M, pH 7.0-7.4), and dialyze overnight at 4 °C using PBS buffer to obtain IgY antibody. Divide the IgY antibody solution into centrifuge tubes, label them, and store them at -80 °C.